ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts [Seeking Alpha]
ArriVent BioPharma, Inc. (AVBP)
Company Research
Source: Seeking Alpha
Firmonertinib has continued to deliver encouraging efficacy with a tolerable safety profile across treated patients. Under conservative assumptions, there is an asymmetric valuation setup. With a solid cash runway and an industry facing an unprecedented patent cliff, AVBP is well-positioned both as a standalone asset and as a potential M&A candidate. Wirestock/iStock via Getty Images Here at the Lab, we generally do not cover late-stage clinical oncology companies. Still, this time, ArriVent BioPharma ( AVBP ) warrants an exception due to Firmonertinib's near-term catalysts (Fig. 1) and the Chinese asset's origin profile. This remains a This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of AVBP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship wi
Show less
Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVBP alerts
High impacting ArriVent BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AVBP
News
- ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
- ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung CancerGlobeNewswire
- Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443BPR Newswire
- ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.MarketBeat
AVBP
Earnings
- 11/10/25 - Miss
AVBP
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- AVBP's page on the SEC website